Saverio Gentile, Ph.D.



Group Leader with 15 years of experience in ion channels, cancer biology, pharmacology, signal transduction supported by field research and professional work in cancer therapeutics, neurobiology, endocrinology and cardiovascular. Provided leadership to research groups that advanced pharmacological manipulation of ion channels into preclinical and clinical studies. Strong communication and team-building skills.

James Herrington, Ph.D.




Jim has over 15 years of experience in biopharma at Merck, Genentech and Bristol-Myers Squibb where he served as project lead for small molecule and biologics programs in neuroscience and metabolic disorders. He has extensive knowledge on many target classes including ion channels, GPCRs and enzymes. Jim is an expert in the development of assays based on automated electrophysiology, ion-specific and membrane potential dyes, and biochemical readouts. As a specialist in target validation and high-throughput screening, Jim has designed and implemented several HTS campaigns leading to clinical-stage compounds. He has published over 50 papers in the field of ion channel pharmacology, cell signaling and screening. Since 2017, Jim has been a project lead in the high throughput screening group at the Yale Center of Molecular Discovery.

Dorothy Flood, Ph.D.




Dorothy has worked in small to mid-sized pharmaceutical companies for over 20 years in discovery research as a Senior Scientist at the bench to Senior Director of Pharmacology managing CROs. Her work has focused on the nervous system, primarily in neurodegenerative and psychiatric diseases, initially as a neuroanatomist and behaviorist. Most recently she has managed CROs performing the full range of discovery research studies in pharmacology, safety, DMPK, and toxicity studies, and prepared the discovery research documentation for IND submissions. The pharmacology studies have covered receptor binding assays, FLIPR functional assays, electrophysiology from engineered cells to animals, and behavior for GPCR and ligand-gated ion channel targets.